Topical treatment of chemotherapy-induced peripheral neuropathy (CIPN) with high-concentration (179 mg) capsaicin patch in breast cancer patients – results of the QUCIP study
In this study, HCCP shows benefit in managing CIPN in real-world settings. The data demonstrate a sustained and progressive reduction in neuropathic pain and symptomatology, confirming the clinical benefit of repeated treatment observed in former clinical trials. HCCP treatment has also the potential to significantly improve the QoL associated with CIPN. The safety profile of HCCP was confirmed, supporting its use in clinical practice.
Authors
- Brigitte Rack (ORCID: https://orcid.org/0000-0002-7539-4839)
- Myriam Heine
- Tamara Quandel
- Catrin Frömter
- Stefan Paepke
- Michael P. Lux (ORCID: https://orcid.org/0000-0002-2781-2178)
- Kristina Veselinovic (ORCID: https://orcid.org/0000-0002-2959-0580)
- R. Sabatowski (ORCID: https://orcid.org/0000-0003-2228-3147)
- Lilit Flöther
- Petra Krabisch (ORCID: https://orcid.org/0009-0001-1433-2693)
Institutions
- Klinikum St. Georg (DE)
- TUM Klinikum (DE)
- Brüderkrankenhaus St. Josef Paderborn (DE)
- University Hospital in Halle (DE)
- University Hospital Ulm (DE)
- University Hospital Carl Gustav Carus (DE)
- Klinikum Chemnitz (DE)
- Grünenthal Group (Germany) (DE)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2024-09-06
- DOI
- https://doi.org/10.3389/fonc.2024.1452099
- Citations
- 5
- Primary Topic
- Cancer Treatment and Pharmacology
- Type
- article
- Field-Weighted Citation Impact
- 1.41